First Time Loading...

MorphoSys AG
XETRA:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
XETRA:MOR
Watchlist
Price: 66.65 EUR 0.83% Market Closed
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

MOR Price Targets Summary
MorphoSys AG

Wall Street analysts forecast MOR stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MOR is 57.12 EUR with a low forecast of 17.17 EUR and a high forecast of 71.4 EUR.

MOR Lowest Forecast
Wall Street Target
17.17 EUR
74% Downside
MOR Average Forecast
Wall Street Target
57.12 EUR
14% Downside
MOR Highest Forecast
Wall Street Target
71.4 EUR
7% Upside
Lowest
Price Target
17.17 EUR
74% Downside
Average
Price Target
57.12 EUR
14% Downside
Highest
Price Target
71.4 EUR
7% Upside
MorphoSys AG Competitors:
Price Targets
B
BLRX
BioLine RX Ltd
80% Downside
1672
Ascletis Pharma Inc
114% Upside
CYTH
Cyclo Therapeutics Inc
122% Upside
DYAI
Dyadic International Inc
410% Upside
B
BLRX
BioLine RX Ltd
80% Downside
1672
Ascletis Pharma Inc
114% Upside
CYTH
Cyclo Therapeutics Inc
122% Upside
DYAI
Dyadic International Inc
410% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
4% Upside
P
214450
PharmaResearch Co Ltd
24% Upside
CRIS
Curis Inc
36% Upside
TWST
Twist Bioscience Corp
4% Upside

Revenue
Forecast

Revenue Estimate
MorphoSys AG

For the last 8 years the compound annual growth rate for MorphoSys AG's revenue is 11%. The projected CAGR for the next 3 years is 21%.

11%
Past Growth
21%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
MorphoSys AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
MorphoSys AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

See Also

Summary
MOR intrinsic value, competitors valuation, and company profile.
DCF Valuation
MOR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MOR stock valuation using valuation multiples.
Wall Street Estimates
MOR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MOR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MOR's stock price target?
Price Target
57.12 EUR

According to Wall Street analysts, the average 1-year price target for MOR is 57.12 EUR with a low forecast of 17.17 EUR and a high forecast of 71.4 EUR.

What is MorphoSys AG's Revenue forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for MorphoSys AG's revenue is 11%. The projected CAGR for the next 3 years is 21%.

ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.